InvestSMART

Amplia Therapeutics Limited (ASX:ATX)

ALERT: Price-sensitive ASX Announcement for ATX
Current share price for ATX : $0.150 -0.015 (-9.09%)+
Announcement
Release
28 Apr 2026 9:38AM
Price at Release
$0.165
Full Release
download
Summary
Amplia Therapeutics Limited has made significant progress in developing narmafotinib, a FAK inhibitor, for treating fibrotic cancers, particularly pancreatic cancer. The ACCENT trial results demonstrated improved survival rates when narmafotinib was used with chemotherapy. However, the AMPLICITY trial encountered dose-limiting toxicities unrelated to narmafotinib. The company maintains a robust cash position of $27.9 million, despite investing heavily in research and development. They have completed large-scale narmafotinib production to GMP standards and are preparing for further regulatory engagement and new clinical trials.
Key Points
  • Amplia Therapeutics Limited is developing narmafotinib, a FAK inhibitor, for fibrotic cancers like pancreatic cancer.
  • The ACCENT trial showed narmafotinib with chemotherapy improved survival rates in pancreatic cancer patients.
  • The AMPLICITY trial, exploring narmafotinib with FOLFIRINOX, faced challenges with dose-limiting toxicity.
  • Amplia's cash position is strong with $27.9 million as of March 2026, despite $3.5 million in net operating cash outflows.
  • Significant funds were allocated to research, development, and administration costs.
  • Large-scale production of narmafotinib to GMP standards has been completed, enhancing readiness for Phase 3 trials.
  • The company is focusing on regulatory engagement with the US FDA and planning new clinical studies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.